All In Biotech

Drug Trial Radar · NCT05613088

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

106

Actual

Start

Feb 1, 2023

Primary completion

Jun 17, 2024

Study completion Sep 10, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Eisai Inc.
First posted
Nov 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.

Conditions

  • Neoplasms, Ovarian

Interventions

  • MORAb-202Drug

    Specified dose on specified days

  • PaclitaxelDrug

    Specified dose on specified days

  • Pegylated Liposomal Doxorubicin (PLD)Drug

    Specified dose on specified days

  • TopotecanDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator AssessmentTime frame: From the date of randomization to the date of first objectively-documented progression or the date of subsequent therapy (Up to approximately 70 weeks)
  2. Number of Participants With Treatment-Related Adverse Event (TRAEs) Leading to Discontinuation Within 6 Months From First DoseTime frame: From first dose of study medication up to 6 months

Locations

50 sites in 9 countries. Site status is shown where the registry gives one.

  • Local Institution - 0065

    Sacramento, California

  • Local Institution - 0025

    San Francisco, California

  • Local Institution - 0078

    Whittier, California

  • Local Institution - 0081

    South Bend, Indiana

  • Local Institution - 0043

    Kansas City, Kansas

  • Local Institution - 0023

    Canton, Ohio

  • Local Institution - 0061

    Columbus, Ohio

  • Local Institution - 0044

    Nashville, Tennessee

  • Local Institution - 0082

    Salt Lake City, Utah

  • Local Institution - 0042

    Spokane, Washington

  • Local Institution - 0016

    Sydney, New South Wales, Australia

  • Local Institution - 0017

    Waratah, New South Wales, Australia

  • Local Institution - 0031

    Chermside, Queensland, Australia

  • Local Institution - 0015

    Clayton, Victoria, Australia

  • Local Institution - 0027

    Malvern, Victoria, Australia

  • Local Institution - 0058

    Nedlands, Western Australia, Australia

  • Local Institution - 0012

    Brussels, Belgium

  • Local Institution - 0045

    Liège, Belgium

  • Local Institution - 0032

    Leuven, VBR, Belgium

  • Local Institution - 0013

    Namur, WNA, Belgium

  • Local Institution - 0036

    Santiago, Chile

  • Local Institution - 0029

    Temuco, Chile

  • Local Institution - 0030

    Santiago, RM, Chile

  • Local Institution - 0054

    Haifa, Israel

  • Local Institution - 0080

    Jerusalem, Israel

  • Local Institution - 0055

    Ramat Gan, Israel

  • Local Institution - 0048

    Tel Aviv, Israel

  • Local Institution - 0046

    Jerusaelm, JM, Israel

  • Local Institution - 0002

    Brescia, Italy

  • Local Institution - 0003

    Bologna, BO, Italy

  • Local Institution - 0011

    Milan, MI, Italy

  • Local Institution - 0009

    Milan, MI, Italy

  • Local Institution - 0010

    Roma, RM, Italy

  • Local Institution - 0018

    Akashi, Hyogo, Japan

  • Local Institution - 0019

    Chūōku, Japan

  • Local Institution - 0014

    Hidaka-shi, Japan

  • Local Institution - 0004

    Kurume-Shi, Japan

  • Local Institution - 0037

    Tokyo, Japan

  • Local Institution - 0056

    Seoul, South Korea

  • Local Institution - 0049

    Seoul, South Korea

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.